NanoString Makes Moves to Push Into Molecular Diagnostics Market

A recent licensing agreement for a panel of genes for breast cancer detection "marks really the debut of NanoString as a serious diagnostics developer," President and CEO Brad Gray said.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories